Effect of beta blocker on breast cancer progression in minority population.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12564-e12564
Author(s):  
Rajshekhar Chakraborty ◽  
Shiva Kumar Reddy Mukkamalla ◽  
Natalia Calderon ◽  
Linda Bulone

e12564 Background: Recent pharmaco-epidemiological studies have shown positive effects of beta blockers (BB) on breast cancer progression, recurrence, metastasis, and cancer specific mortality. To the best of our knowledge none of these studies specifically targeted the minority population. The purpose of our study was to determine the effect of beta blockers on the Progression Free Survival (PFS) of breast cancer patients belonging to the minority subgroup of US population. Methods: We retrospectively reviewed 142 consecutive cases of breast cancer in a city hospital in Queens County of New York City (Asians 36%, Blacks 42%, Hispanics 18% and Whites 4%) diagnosed between January 2007 and December 2009. Patients using beta blockers prior to diagnosis were compared to those who were not on any in terms of PFS after adjusting for the confounding effect of stage at presentation. Kaplan-Meier survival curves were used to look for any significant difference in the PFS between these two groups in minority population. Results: Patients on beta blockers (n=25) were compared to those who were not (n=111). The median follow-up time of this study was 54 months. The study population was stratified according to the stage of presentation (Stage I=32%, Stage II=36%, Stage III=22%, Stage IV=10%).Using Kaplan Meier survival analysis we found significant differences in PFS of patients in stages II and IV (Wilcoxon Test p<0.0001, Log-Rank Test p<0.0001). There was no progression of disease in stage I irrespective of beta blocker intake. In stage II, PFS at the end of study in patients on BB vs. not on BB was 91% vs. 87%. In stage IV the PFS was 100% vs. 10% in patients on BB vs. not on BB. However, in stage III the PFS was better in patients not on BB, which could be explained by the small number of patients on BB (50% vs. 77% in BB vs. no BB subgroup). Conclusions: In this study of breast cancer PFS in minority population, we found that beta blocker use was associated with improved PFS in stages II and IV. However, additional studies with larger sample size are required to substantiate this finding.

2020 ◽  
Vol 28 (1) ◽  
pp. 138-151
Author(s):  
Kelly A. Stahl ◽  
Elizabeth J. Olecki ◽  
Matthew E. Dixon ◽  
June S. Peng ◽  
Madeline B. Torres ◽  
...  

Gastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. The National Cancer Database was used to identify gastric adenocarcinoma patients from 2004–2016. Chi-square tests were used to examine subgroup differences between disease stages: Stage I, II/III and IV. Multivariate analyses identified factors associated with the receipt of guideline concordant care. The Kaplan–Meier method was used to assess three-year overall survival. The final cohort included 108,150 patients: 23,584 Stage I, 40,216 Stage II/III, and 44,350 Stage IV. Stage specific guideline concordant care was received in only 73% of patients with Stage I disease and 51% of patients with Stage II/III disease. Patients who received guideline consistent care had significantly improved survival compared to those who did not. Overall, we found only moderate improvement in guideline adherence and three-year overall survival during the 13-year study time period. This study showed underutilization of stage specific guideline concordant care for stage I and II/III disease.


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22228-e22228
Author(s):  
M. Ghosn ◽  
C. Hajj ◽  
F. Nasr ◽  
F. El Karak ◽  
G. Abadjian ◽  
...  

e22228 Background: Breast cancer (BC) is the most common malignancy in women in Lebanon. Triple negative (TN) phenotype is known to be associated with an increased likelihood of recurrence and death. The purpose of this study is to determine the incidence, characteristics and survival of TN BC patients in a Medical Oncology department in a University Hospital in Lebanon. Methods: We retrospectively reviewed the pathology of all women with breast cancer that were seen in our institution between 1997 and 2008. TN BC patients (pts) were defined as those that were negative for all 3 receptors (estrogen, progesterone and HER2neu on immunohistochemistry). Pts' characteristics and survival of TN women were analyzed. Results: Of the 1599 breast cancer pts, 155 (9.7%) had a triple negative phenotype. Median age was 52 years. A positive family history of breast/ovarian cancer was found in 15 pts (10%). Pathology studies showed: invasive ductal carcinoma component in 138 pts (89%), pure medullary carcinoma in 7 pts (5%), pure invasive lobular carcinoma in 6 pts (4%), pure mucinous carcinoma in 3 pts (2%) and epidermoid carcinoma in 1 pt (1%). A grade III was found in 98 of specimens (63%). Twenty-six pts (17%) presented with stage I, 73 (47%) with stage II, 37 (24%) with stage III and 19 (12%) with stage IV. Twelve percent had inflammatory breast cancer. After a median follow up of 17 months (mths), 43 pts had relapsed (5 stage I, 18 stage II and 20 stage III). The most common sites of relapse were brain (in 20 % of cases), lungs (in 20% of cases) and bone (in 11% of cases). Five- year disease free survival and 5-year overall survival were respectively 75% and 88% for stage I, 58% and 72% for stage II and 40% and 63% for stage III. Adjuvant therapy was administered to 96% of pts among which a taxane-based regimen was used in 38% of cases . Median survival for stage IV was 19 mths with a first line taxane-based regimen used in 50% of cases. Conclusions: The incidence of TN BC in Lebanon is similar to that described in the literature. It has an aggressive course. Focus on understanding the biology of this particular BC subtype is essential for determining targets for future therapeutic options. No significant financial relationships to disclose.


Author(s):  
Dr. Amol R. R. Rajhans, MD ◽  
Dr. Deepak S. Howale

Breast cancer is the most common invasive cancer in women, and the second main cause of cancer death in women, after lung cancer. Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin. In 2017, around 252, 710 new diagnoses of breast cancer are expected in women, and around 40,610 women are likely to die from the disease. Awareness of the symptoms and the need for screening are important ways of reducing the risk. Material and Methods: This retrospective study was carried out in the department of Pathology, DCP Consultant Pathologist Shashwat Hospitals, Pune, a total of 38 retrospective breast carcinoma tissues were obtained from female patients. Representative paraffin blocks and haematoxylin and eosin (HandE)-stained sections were retrieved from the pathology department. The patients' records were reviewed to look for the patient age and the clinical stage of the disease. The stage of the cancer was reported according to the American Joint Committee of Cancer. As tissue and patient data was collected in an anonymous way no written or informed consent was required for the study purpose. Results and Observations: According to data by clinical staging Stage I, Stage II, Stage III and Stage IV were 16 (42.11%), 11(28.95%), 7 (18.42%) and 4 (10.53%) respectively. According to histology Stage I, Stage II, Stage III and Stage IV were 2 (5.26%), 11(28.95%), 24 (63.16%) and 1 (2.63%) respectively. Hand E-stained sections showed that tumour-infiltrating lymphocytes (TILs) were present in 31 of the 38 carcinomas (81.58%). Majority of theTILs were T lymphocytes and was present in all 31 cases. CD4+ cells were seen31 patients and CD 8+ were seen in 25 cases. B cells were seen in 21 cases. TILs were analysed according to the clinical stage of breast cancer, stages III and IV tumors showed significantly higher densities of total lymphocytes, T lymphocytes, and CD4+ lymphocytes as compared to stage II tumors. Lymphocyte immuno phenotypes and the total TILs also showed a high significantly positive correlation between each lymphocyte population/subpopulation and the total TILs. Conclusion: T and B lymphocytes were expressed in breast carcinoma with High prevalence of T lymphocytes CD4+ cells. However larger no of cases are required to confirm the findings and extensive large studies are required.


2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 23-23
Author(s):  
NA Kaddi ◽  
NA Berrada ◽  
HA Errihani

Background: Breast cancer is both the most common and deadliest cancer among women in the world. The objective of this study was to assess breast cancer survival rates. Material and Methods: Prospective study conducted at the National Institute of oncology (INO) Sidi Mohamed Ben Abdellah Rabat .diagnosed patients with cancer from 2013 to 2015. The date of inclusion in the study is the date of histological confirmation of cancer. The survival assessment performed by the Kaplan Meier method, and the comparison between the different classes of a variable was performed by the Log Rank test. Results: 931 cases were collected during this study. According to molecular classification 59% of luminal patients, 25% positive human epidermal growth factor receptors (her2 positive) and 16% basal. The percentage of survival at 5 years, for luminal stage I 93%, stage II 92%, stage III 74% and stage IV 25% ;as well as for basal stage I 92%, stage II 80%, stage III 53% and stage IV 10% ; then the her2 positive stage I 100%, stage II 75% and stage III 70%. Conclusion: The discovery of metastatic cancer decreased breast cancer survival rate, hence the importance of Early Detection Awareness.


2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Ayman M. Ibrahim ◽  
Alan Bilsland ◽  
Steffen Rickelt ◽  
Joanna S. Morris ◽  
Torsten Stein

Abstract Background During pregnancy, the mouse mammary ductal epithelium branches and grows into the surrounding stroma, requiring extensive extracellular matrix (ECM) and tissue remodelling. It therefore shows parallels to cancer invasion. We hypothesised that similar molecular mechanisms may be utilised in both processes, and that assessment of the stromal changes during pregnancy-associated branching may depict the stromal involvement during human breast cancer progression. Methods Immunohistochemistry (IHC) was employed to assess the alterations within the mouse mammary gland extracellular matrix during early pregnancy when lateral branching of the primary ductal epithelium is initiated. Primary mouse mammary fibroblasts from three-day pregnant and age-matched non-pregnant control mice, respectively, were 3D co-cultured with mammary epithelial cells to assess differences in their abilities to induce branching morphogenesis in vitro. Transcriptome analysis was performed to identify the underlying molecular changes. A signature of the human orthologues of the differentially expressed matrisome RNAs was analysed by Kaplan–Meier and multi-variate analysis in two large breast cancer RNA datasets (Gene expression-based Outcome for Breast cancer Online (GOBO) und Kaplan–Meier Plotter), respectively, to test for similarities in expression between early-pregnancy mouse mammary gland development and breast cancer progression. Results The ECM surrounding the primary ductal network showed significant differences in collagen and basement membrane protein distribution early during pregnancy. Pregnancy-associated fibroblasts (PAFs) significantly enhanced branching initiation compared to age-matched control fibroblast. A combined signature of 64 differentially expressed RNAs, encoding matrisome proteins, was a strong prognostic indicator of distant metastasis-free survival (DMFS) independent of other clinical parameters. The prognostic power could be significantly strengthened by using only a subset of 18 RNAs (LogRank P ≤ 1.00e−13; Hazard ratio (HR) = 2.42 (1.8–3.26); p = 5.61e−09). The prognostic power was confirmed in a second breast cancer dataset, as well as in datasets from ovarian and lung cancer patients. Conclusions Our results describe for the first time the early stromal changes that accompany pregnancy-associated branching morphogenesis in mice, specify the early pregnancy-associated molecular alterations in mouse mammary fibroblasts, and identify a matrisome signature as a strong prognostic indicator of human breast cancer progression, with particular strength in oestrogen receptor (ER)-negative breast cancers.


2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21163-21163
Author(s):  
G. D. Krygier ◽  
E. Barrios ◽  
S. Cataldi ◽  
A. Vazquez ◽  
R. Alonso ◽  
...  

21163 Background: Breast cancer is the most common tumor arising in Uruguaian women accounting for 1,930 patients/year (adjusted incidence ratio 83.1/100,000) with 637 death/year (adjusted mortality ratio 24.1/100,000). Both incidence and mortality rank Uruguay at the top of the latinamerican countries ( IARC-GloboCan 2002). We are presenting our final results with 1,906 patients followed during a 21 year period in the biggest private Institution in our country (CENDIMA) and probably amongst all other latin-american countries. Methods: Although this study was initially designed to find a relationship between prognostic factors and survival parameters: OS (overall survival) and DFS (disease free survival) it also describes the epidemiological features of a big breast cancer population in the top ranked country for breast cancer incidence and mortality in Latin America. Statistical analysis was calculated with SPSS (11.0 version) and SAS (6.0 version) programs. OS and DFS results were obtained through Kaplan Meier method. Log rank test was implemented for univariate analysis and Cox proportional hazard rates were used for multivariate analysis. Results: The median age at diagnosis was 61.0 (SD 13.5). Ductal infiltrating carcinoma (DIC) accounted for more than 80% of patients and 56% were node negative (N0) patients at diagnosis. Stratification was: Stage 0: 8.6%, Stage I: 31.5%, Stage II: 41.8%, Stage III: 16.6%, Stage IV: 1.5%. For OS, the axillary status and hystologic grade showed the highest relative ratio (RR) value: 2.49 and 2.40. The nodal status was the main prognostic factor related to DFS with a 2.2 RR. The five and ten year survival rate was: 0.96 and 0.92 (stage I), 0.84 and 0.71 (stage II), 0.71 and 0.56 (stage III) and 0.39 and 0.29 (stage IV) respectively. Conclusions: This is the final analysis of our population in Uruguay representing the biggest report in breast pathology in a latin-american country with a long follow up period (more than 20 years). Our “good” survival results may reflect the initially low risk population at diagnosis (56% node negative, 40.1% stage 0-I ). Nodal status, histologic grade and staging at diagnosis were independent prognostic factors in univariate and multivariate analysis. No significant financial relationships to disclose.


2005 ◽  
Vol 3 (3) ◽  
pp. 0-0
Author(s):  
Algirdas Jackevičius ◽  
Leonarda Šarakauskienė ◽  
Valerijus Ostapenko ◽  
Saulius Bružas ◽  
Juozas Kurtinaitis ◽  
...  

Algirdas Jackevičius, Leonarda Šarakauskienė, Valerijus Ostapenko, Saulius Bružas, Juozas Kurtinaitis, Algimantas MudėnasVilniaus universiteto Onkologijos institutas,Santariškių g.1, LT-08660 VilniusKauno medicinos universiteto Onkologijos ligoninė,Volungių g. 16, LT-45434 KaunasEl paštas: [email protected] Įvadas / tikslas Vyrų krūties vėžys yra reta onkologinė liga. Šiame straipsnyje pateikiame 75 ligonių, gydytų dviejose onkologijos ligoninėse, klinikinius duomenis, tiesioginius ir vėlyvuosius gydymo rezultatus. Ligoniai ir metodai Straipsnyje nagrinėjami Vilniaus universiteto Onkologijos instituto klinikoje ir Kauno universiteto Onkologijos ligoninėje1988–2003 metais gydytų 75 vyrų, sirgusių krūties vėžiu, klinikiniai duomenys. Ligonių amžiaus vidurkis – 69,2 metų (jauniausias 41, vyriausias 90 metų). Aštuoniems (10,7%) ligoniams diagnozuotas pirmos stadijos vėžys, 35 (46,7%) – antros, 22 (29,3%) – trečios, 10 (13,3%) ligonių – ketvirtos. Pagal histologinius vėžio tipus dažniausiai diagnozuota intraduktalinė karcinoma – 40 ligonių, 8 ligoniams – lobulinė karcinoma, tačiau 14 ligonių vėžio histologinis tipas nenustatytas. Dažniausiai, t. y. 53 ligoniams, buvo atlikta modifikuota Maddeno mastektomija, aštuoniems – paprastoji mastektomija, 8 ligoniams taikyta spindulinė terapija, 6 ligoniams dėl sunkių gretutinių ligų – simptominis gydymas. 37 ligoniai gydyti kombinuotu būdų: 30 – spinduline terapija, 5 – chemoterapija, 2 – abiem gydymo metodais. Rezultatai Vėlyvieji gydymo rezultatai nebuvo geri: iš 75 gyvena 28 liginiai, 47 mirė. Penkerius metus išgyveno 83,3% (95% PI 27,3–97,5) sergančiųjų pirmos stadijos krūties vėžiu, 69,6% (95% PI 49,1–83,1) – antros stadijos ir tik 6,2% (95% PI 4,2–24,2) – trečios. Nė vienas ligonis, kuriam diagnozuota ketvirta ligos stadija, neišgyveno penkerių metų. Išvados Lietuvoje vyrų sergamumas krūties vėžiu per pastaruosius metus nepakito. Nemažai vyrų buvo gydyti nuo IIIB stadijos krūties vėžio, kai navikas jau buvo lokaliai išplitęs ir susiformavo vėžinė opa. Vyrų, sergančių trečios stadijos krūties vėžiu, prognozė yra blogesnė negu moterų. Ligos stadija nulemia ligonių gyvenimo trukmę, tai patvirtina statistinis vėlyvųjų gydymo rezultatų skaičiavimas. Reikšminiai žodžiai: vyrų krūties vėžys, diagnostika, gydymas, vėlyvieji rezultatai The diagnostics and treatment of male breast carcinoma Algirdas Jackevičius, Leonarda Šarakauskienė, Valerijus Ostapenko, Saulius Bružas, Juozas Kurtinaitis, Algimantas MudėnasVilnius University Institute of Oncology,Santariškių str. 1, LT-08660 Vilnius, LithuaniaKaunas Medical University Oncological Hospital,Volungių str. 16, LT-45434, Kaunas, LithuaniaE-mail: [email protected] Background / objective Male breast cancer is an uncommon oncological disease. In this paper, we have analysed the results of treatment of 75 patients treated in two oncologycal clinics. Patients and methods We analysed 75 male patients treated in 1988–2003 in the clinics of the Institute of Oncology of Vilnius University and Hospital of Oncology of Kaunas University of Medicine. The mean age of patients was 69.2 years (range, 46–90 years). The staging of disease: stage I 8 (10.7%) patients, stage II 35 (46.7%), stage III 22 (29.3%). Ten (13.3%) patients were treated in stage IV of the disease. The most common method of treatment was radical mastectomy by Madden which was performed in 53 cases. In 8 cases mastectomy simplex was performed. Eight patients received radiotherapy. The patients received this conservative treatment in late stages of the disease. In seven cases the patients were in poor health state, and only palliative treatment was applied. 37 patients received combined treatment: 30 patients were treated with radiotherapy, two patients received radiotherapy and chemotherapy, in 5 cases after mastectomy the patients were treated with chemotherapy. Results The follow-up results were not satisfactory: from 75 patients 28 patients are alive and 47 died. The 5-year survival of the patients according to the stage of disease: 83.3% (95% CI 27.3–97.5) of patients in stage I, 69.6% (95% CI 49.1–83.1) in stage II, stage III 6.2% (95% CI 4.2–24.2). In this period, all patients in stage IV of the disease died. Conclusions The incidence of male breast cancer in Lithuania is low, and over the last years has remained at the same level. Many of our patients had ulceration of tumor and were treated in stage III B of the disease. The prognosis of male breast cancer in stage III of the disease is worse than of female breast cancer of the same stage. The stage of the disease was statistically significant for the survival of patients. Keywords: male breast carcinoma, diagnosis, treatment, follow-up results


2014 ◽  
Author(s):  
Mattia Capulli ◽  
Adriano Angelucci ◽  
Anna Teti ◽  
Patrizia Sanita ◽  
Luca Ventura ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document